MA40863B1 - Thiazoles en tant que modulateurs de roryt - Google Patents

Thiazoles en tant que modulateurs de roryt

Info

Publication number
MA40863B1
MA40863B1 MA40863A MA40863A MA40863B1 MA 40863 B1 MA40863 B1 MA 40863B1 MA 40863 A MA40863 A MA 40863A MA 40863 A MA40863 A MA 40863A MA 40863 B1 MA40863 B1 MA 40863B1
Authority
MA
Morocco
Prior art keywords
compound
relates
roryt
thiazoles
modulators
Prior art date
Application number
MA40863A
Other languages
English (en)
Other versions
MA40863A (fr
Inventor
Christoph Steeneck
Christian Gege
Olaf Kinzel
Gerald Kleymann
Thomas Hoffmann
Steven Goldberg
Anne Fourie
Xiaohua Xue
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40863A publication Critical patent/MA40863A/fr
Publication of MA40863B1 publication Critical patent/MA40863B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés de formule i, dans laquelle r1, r2, r3, r4, r5, r7, r8 et (a) sont tels que définis dans la spécification. L'invention concerne également un composé de formule i destiné à être utilisé dans un procédé pour traiter ou atténuer un syndrome, un trouble ou une maladie, ledit syndrome, ledit trouble ou ladite maladie étant la polyarthrite rhumatoïde ou le psoriasis. L'invention concerne également un composé destiné à être utilisé dans un procédé pour moduler l'activité de ror?T chez un mammifère par administration d'une quantité thérapeutiquement efficace d'au moins un composé de la revendication 1.
MA40863A 2014-10-30 2015-10-30 Thiazoles en tant que modulateurs de roryt MA40863B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072614P 2014-10-30 2014-10-30
PCT/US2015/058198 WO2016069976A1 (fr) 2014-10-30 2015-10-30 Thiazoles utilisés comme modulateurs de roryt
EP15794421.6A EP3212641B1 (fr) 2014-10-30 2015-10-30 Thiazoles en tant que modulateurs de roryt

Publications (2)

Publication Number Publication Date
MA40863A MA40863A (fr) 2017-09-06
MA40863B1 true MA40863B1 (fr) 2018-12-31

Family

ID=54541228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40863A MA40863B1 (fr) 2014-10-30 2015-10-30 Thiazoles en tant que modulateurs de roryt

Country Status (23)

Country Link
US (2) US9861618B2 (fr)
EP (1) EP3212641B1 (fr)
JP (1) JP6661630B2 (fr)
KR (1) KR20170078748A (fr)
CN (1) CN107108598B (fr)
AU (1) AU2015339089B2 (fr)
BR (1) BR112017008842A2 (fr)
CA (1) CA2965515A1 (fr)
CY (1) CY1121285T1 (fr)
DK (1) DK3212641T3 (fr)
ES (1) ES2708025T3 (fr)
HR (1) HRP20190174T1 (fr)
IL (1) IL251851A0 (fr)
LT (1) LT3212641T (fr)
MA (1) MA40863B1 (fr)
ME (1) ME03306B (fr)
PL (1) PL3212641T3 (fr)
PT (1) PT3212641T (fr)
RS (1) RS58250B1 (fr)
SI (1) SI3212641T1 (fr)
SM (1) SMT201900082T1 (fr)
TR (1) TR201820513T4 (fr)
WO (1) WO2016069976A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
LT3212641T (lt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazolai, kaip roryt moduliatoriai
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
US11230555B2 (en) 2018-03-12 2022-01-25 Escalier Biosciences B.V. Bicyclic RORγ modulators
EP3765020A4 (fr) 2018-03-12 2021-09-22 Escalier Biosciences B.V. Modulateurs de ror-gamma spirocycliques
JP2021529161A (ja) 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
CA3103770A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Imidazoles substitues par phenyle et pyridinyle utilises en tant que modulateurs de roryt
WO2019244001A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles en tant que modulateurs de roryt

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
HUP0303829A3 (en) 2001-04-16 2006-02-28 Tanabe Seiyaku Co Large conductance calcium-acitvated k channel opener compounds, use thereof and pharmaceutical compositions containing them
EA007933B1 (ru) * 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
WO2007087427A2 (fr) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Composes thiazole et thiadiazole destines a des utilisations associees a une inflammation et au système immunitaire
WO2008064318A2 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes périphériques
WO2008064317A1 (fr) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Composés actifs de récepteurs opioïdes lipophiles
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
EP2586311B1 (fr) * 2008-07-17 2016-12-14 Bayer CropScience AG Liaisons hétérocycliques en tant que moyen de lutte contre les parasites
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011112264A1 (fr) 2010-03-11 2011-09-15 New York University Composés en tant que modulateurs de rorϒt et leurs utilisations
EP3002008B8 (fr) 2010-03-11 2018-10-24 New York University Composés d'amido comme modulateurs roryt et leurs utilisations
WO2011115892A1 (fr) 2010-03-15 2011-09-22 Griffin Patrick R Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
WO2012027965A1 (fr) * 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
WO2012074547A2 (fr) 2010-11-29 2012-06-07 New York University COMPOSÉS STÉROÏDES COMME MODULATEURS DE RORγT ET LEURS UTILISATIONS
KR101958699B1 (ko) 2010-12-28 2019-03-15 라이온 가부시키가이샤 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램
WO2012129491A1 (fr) * 2011-03-24 2012-09-27 Abbott Laboratories Modulateurs de trpv3
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
EP2738170B1 (fr) 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Composé hétérocyclique
JP2014528933A (ja) 2011-09-09 2014-10-30 ニューヨーク ユニバーシティ ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014195321A1 (fr) 2013-06-04 2014-12-11 Acturum Life Science AB Composés de triazole et utilisation de ces derniers en tant que modulateurs de la gamma-sécrétase
US9663469B2 (en) 2013-09-09 2017-05-30 Bristol-Myers Squibb Company RORγ modulators
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
CN105555768B (zh) 2013-09-20 2018-10-16 百时美施贵宝公司 RORγ调节剂
US9738600B2 (en) 2013-12-05 2017-08-22 Lead Pharma Cel Models Ip B.V. ROR gamma (RORγ) modulators
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
JP6530764B2 (ja) 2014-01-06 2019-06-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子としてのピロリジニルスルホン誘導体およびその使用
US9637455B2 (en) 2014-01-06 2017-05-02 Bristol-Myers Squibb Company Heterocyclic sulfone RORγ modulators
ES2704460T3 (es) 2014-01-06 2019-03-18 Bristol Myers Squibb Co Moduladores de ROR gamma de ciclohexilsulfona
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
KR20170075787A (ko) 2014-10-30 2017-07-03 얀센 파마슈티카 엔.브이. RORγt의 조절제로서의 아미드 치환된 티아졸
LT3212641T (lt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazolai, kaip roryt moduliatoriai

Also Published As

Publication number Publication date
ES2708025T3 (es) 2019-04-08
US20160120850A1 (en) 2016-05-05
EP3212641B1 (fr) 2018-12-05
WO2016069976A1 (fr) 2016-05-06
PT3212641T (pt) 2019-02-11
IL251851A0 (en) 2017-06-29
BR112017008842A2 (pt) 2017-12-26
RS58250B1 (sr) 2019-03-29
TR201820513T4 (tr) 2019-02-21
US9861618B2 (en) 2018-01-09
CN107108598A (zh) 2017-08-29
US20180064690A1 (en) 2018-03-08
AU2015339089A1 (en) 2017-05-11
US10080744B2 (en) 2018-09-25
AU2015339089B2 (en) 2020-07-16
CA2965515A1 (fr) 2016-05-06
PL3212641T3 (pl) 2019-05-31
KR20170078748A (ko) 2017-07-07
MA40863A (fr) 2017-09-06
HRP20190174T1 (hr) 2019-03-22
CN107108598B (zh) 2020-11-17
DK3212641T3 (en) 2019-03-04
SMT201900082T1 (it) 2019-02-28
SI3212641T1 (sl) 2019-02-28
JP6661630B2 (ja) 2020-03-11
LT3212641T (lt) 2019-02-11
EP3212641A1 (fr) 2017-09-06
ME03306B (fr) 2019-10-20
JP2017534626A (ja) 2017-11-24
CY1121285T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
MA40863B1 (fr) Thiazoles en tant que modulateurs de roryt
MA40865B1 (fr) Thiazoles à substitution amide utilisés comme modulateurs de rorgammat
MA40873B1 (fr) Alcools trifluorométhylés utilisés comme modulateurs de roryt
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
PH12015500817A1 (en) Methylene linked quinolinyl modulators of ror-gamma-t
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA40290A1 (fr) Agents immunorégulateurs
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA47217B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MX2018013143A (es) 6-aminopiridin-3-il tiazoles como moduladores de ror?t.
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
BR112016008201A2 (pt) Moduladores de quinolinila ligados à heteroarila de roryt